← back to search

Tak W. Mak

Nagasaki University · CA
🔎 Find collaborators in Immunology · Oncology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Immunology · Oncology
Research interest
Research interests include Immune Cell Function and Interaction, T-cell and B-cell Immunology, Immune Response and Inflammation, and Immunotherapy and Immune Responses.
h-index
181
citations
129,865
works
1,559
NIH funding
primary concept
email

Recent publications

Lymphocyte-derived cholinergic circuits modulate germinal center output and B cell activation.
2026cited by 1position: contributordoi
Unveiling the developmental and tumor-suppressive roles of the p53 variant p53psi.
2026cited by 0position: contributordoi
CD28-driven ex vivo generation of stem-like memory CD8<sup>+</sup> T cells bypassing CD3/TCR signaling.
2026cited by 0position: contributordoi
Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer.
2026cited by 0position: contributordoi
B cell-derived acetylcholine mitigates skin inflammation in mice through α9 nicotinic acetylcholine receptor-mediated signaling.
2025cited by 6position: contributordoi
Cholinergic T cells revitalize the tumor immune microenvironment: TIME to ChAT.
2025cited by 3position: contributordoi
LARP4-mediated hypertranslation drives T cell dysfunction in tumors.
2025cited by 3position: contributordoi
Mutant <i>IDH1</i> cooperates with <i>NPM1c</i> or <i>FLT3</i><sup>ITD</sup> to drive distinct myeloid diseases and molecular outcomes.
2025cited by 1position: contributordoi
Cholinergic regulation of thymocyte negative selection.
2025cited by 1position: contributordoi
Author Correction: LARP4-mediated hypertranslation drives T cell dysfunction in tumors.
2025cited by 0position: contributordoi
Calnexin-TREM1 engagement improves tumor antigen presentation and enhances the activation of anti-tumor T cells
2025cited by 0position: contributordoi
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma
Cancer Cell 2024cited by 51position: middledoi
Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair-Deficient Uterine Leiomyosarcoma.
2024cited by 5position: contributordoi
CaSSiDI: novel single-cell "Cluster Similarity Scoring and Distinction Index" reveals critical functions for PirB and context-dependent Cebpb repression.
2024cited by 2position: contributordoi
Development of a highly sensitive platform for protein-protein interaction detection and regulation of T cell function.
2024cited by 1position: contributordoi
Supplementary Figure S4 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi
Supplementary Figure S6 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi
Supplementary Data S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi
Supplementary Figure S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi
Supplementary Data S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi
Supplementary Figure S2 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi
Supplementary Figure S6 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi
Supplementary Figure S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi
Supplementary Table S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi
Supplementary Figure S2 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi
Data from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi
Supplementary Figure S5 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi
Data from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi
Supplementary Figure S5 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi
Supplementary Table S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
2024cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 46 papers (2019–2026)Suet Yi Leung · Chelsea and Westminster Hospital NHS Foundation Trust20 papers (2023–2024)Mark R. Bray · Trevi Therapeutics (United States)20 papers (2022–2024)Kin Long Chow · Queen Mary Hospital19 papers (2024–2024)Ka Yu Tse · Australia New Zealand Gynaecological Oncology Group19 papers (2024–2024)Maximus C.F. Yeung · California State Polytechnic University19 papers (2024–2024)Philip P.C. Ip · Cato Institute19 papers (2024–2024)Alice S.T. Wong · Queen Mary Hospital19 papers (2024–2024)Michael S.Y. Huen · Chinese University of Hong Kong19 papers (2024–2024)Horace H.Y. Lee · Queen Mary Hospital19 papers (2024–2024)Grace H.W. Cheng · BC Cancer Agency19 papers (2024–2024)Ho Shing Wong · 19 papers (2024–2024)Tsz Yan Chong · Queen Mary Hospital19 papers (2024–2024)Hoi Cheong Siu · 19 papers (2024–2024)Jasmine M.K. Ko · University of Hong Kong19 papers (2024–2024)Andrew Wakeham · University Health Network10 papers (2012–2023)Jillian Haight · University Health Network8 papers (2012–2023)Thorsten Berger · University Health Network7 papers (2017–2023)Andrew Elia · University Health Network6 papers (2012–2023)Dirk Brenner · University of Luxembourg6 papers (2012–2017)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Immunology · Oncology →